Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Davidson

Urology Grapevine, TX Medical Doctor

NPI 1568495398 CMS profile 116576

1600 W College St, Suite 140, Grapevine, TX 76051

Open in the dashboard

General payments

$5,695

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Davidson of Grapevine, TX is reported in the CMS Open Payments database as having received $5,695 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,925 61
2024 General $932 41
2023 General $727 36
2022 General $766 37
2021 General $256 15
2020 General $302 14
2019 General $787 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Davidson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Scott Davidson were reported at $1,925. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Scott Davidson Urology median Middle half National median
2019 $787 $480 $147–$1,201 $163
2020 $302 $246 $87–$645 $114
2021 $256 $358 $111–$1,000 $132
2022 $766 $476 $143–$1,263 $149
2023 $727 $560 $168–$1,461 $160
2024 $932 $563 $170–$1,464 $164
2025 $1,925 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dendreon Pharmaceuticals LLC $700 29 payments
  2. Antares Pharma, Inc. $506 26 payments
  3. Ferring Pharmaceuticals Inc. $395 16 payments
  4. Astellas Pharma US Inc $373 20 payments
  5. Pfizer Inc. $367 21 payments
  6. PROCEPT BioRobotics Corporation $333 8 payments
  7. Boston Scientific Corporation $320 14 payments
  8. Merck Sharp & Dohme Corporation $220 10 payments
  9. AbbVie, Inc. $215 9 payments
  10. Janssen Biotech, Inc. $188 4 payments
  11. Other $2,077 95 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,695 252 payments
Products named General payments · program years 2019–2025
  1. PROVENGE $700 29 payments
  2. XTANDI $592 33 payments
  3. XYOSTED $414 22 payments
  4. ADSTILADRIN $366 14 payments
  5. ORGOVYX Oncology $290 15 payments
  6. AQUABEAM ROBOTIC SYSTEM $225 3 payments
  7. TLANDO $215 11 payments
  8. NOCDURNA $197 10 payments
  9. ERLEADA $188 4 payments
  10. ORGOVYX Hormone Therapy $177 8 payments
  11. Other $3,268 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,077

Median for Urology: 1,053

Drug cost

$276,301

Median for Urology: $101,464

Branded share of claims

28.7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 177 $119,817
Orgovyx Relugolix Brand 20 $48,410
Gemtesa Vibegron Brand 70 $42,761
Jatenzo Testosterone Undecanoate Brand 15 $17,872
Elmiron Pentosan Polysulfate Sodium Brand 14 $14,003
Tamsulosin Hcl Generic 774 $10,907
Dutasteride Generic 236 $6,462
Estradiol Generic 46 $3,044
Testosterone Cypionate Generic 53 $2,329
Testosterone Generic 16 $1,659

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$409,888

Of which drugs: $155,432

Medicare patients

774

Average age 74

Services billed

6,504

150 women, 624 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 48%
Ischemic heart disease 39%
Diabetes 27%
Chronic kidney disease 25%
Cancer 24%
Atrial fibrillation 22%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 39 147 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $160
$160 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $152
$152 — —
XYOSTED
  • Antares Pharma, Inc. $72
$72 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $43
  • PFIZER INC. $9
$53 20 —
BOTOX
  • AbbVie, Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record